Photo from wikipedia
In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized… Click to show full abstract
In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects.
Keywords:
fibrosing interstitial;
progressive fibrosing;
lung diseases;
inbuild trial;
interstitial lung;
patients progressive
Journal Title: Respirology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Respirology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!